By Stephen Nakrosis
Shares of RAPT Therapeutics touched an all-time low following news the company terminated its zelnecirnon program after feedback from the Food and Drug Administration.
In the last hour of Monday's regular-trading session, the company's shares were trading 40% lower, at $1.70. Volume at the time topped 6.3 million shares, above the 65-day average volume of 297,600 shares.
Earlier in the day, the stock touched an all-time low of $1.30, before recovering some ground.
Zelnecirnon was being evaluated as a treatment for asthma and atopic dermatitis. The trials were placed on clinical hold by the FDA in February because of a serious adverse event of liver injury requiring transplant in one patient in the atopic dermatitis trial, RAPT said.
The biopharmaceutical company said it is continuing to advance the preclinical pipeline, including next-generation CCR4 compounds, and to pursue licensing opportunities.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
November 11, 2024 15:30 ET (20:30 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。